Trial Profile
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Tinostamustine (Primary)
- Indications Carcinoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Fallopian tube cancer; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Mycosis fungoides; Non-Hodgkin's lymphoma; Ovarian cancer; Peripheral T-cell lymphoma; Peritoneal cancer; Sezary syndrome; Small cell lung cancer; Soft tissue sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Mundipharma GmbH
- 12 Dec 2023 Results (n=48) assessing safety and efficacy findings for tinostamustine in an expansion cohort of patients with CTCL in patients with advanced haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (n=48) reporting safety and efficacy findings from cohort expansion portion of this trial in haematological malignancies patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 20 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.